Understanding Mesothelioma: The Impact of BAP1 and p16 in Accurate Diagnosis
|

The Future of Mesothelioma Diagnosis: A Faster, More Affordable Solution

ByHolly Zink

A new study’s groundbreaking findings show that using both MTAP and p16 IHC can be a powerful tool in diagnosing mesothelioma. This method not only offers a more affordable option but also boasts high accuracy. By simplifying the detection of an important gene, medical professionals can speed up treatment decisions. This gives mesothelioma patients a more efficient and effective path toward recovery. Mesothelioma is a rare and serious type of cancer that affects the lining of the lungs, abdomen, or heart. It is caused by exposure to a harmful substance called asbestos. Diagnosing mesothelioma early is crucial for effective treatment. To diagnose mesothelioma, doctors use a variety of tests, including imaging scans, biopsies, and genetic tests. One important genetic alteration…

Australian Study Reveals New Mesothelioma Biomarker
| | |

Australian Study Reveals New Mesothelioma Biomarker

ByAlex Strauss

A large multi-center Australian study has revealed what researchers say could be an important new biomarker for malignant mesothelioma. Mesothelioma is a virulent cancer of internal body membranes usually caused by exposure to asbestos. As with other cancers, mesothelioma cells produce certain compounds at higher levels than healthy cells do. Micro RNAs, or miRNAs, are short chains of ribonucleic acid, some of which are produced in abundance by cancer cells. Using miRNA microarrays, the Australian researchers profiled plasma samples from patients with malignant mesothelioma and from healthy controls. After reviewing 90 miRNAs previously associated with mesothelioma, they found two – miR-29c and miR-92a – in particularly high amounts. Further testing found a total of 15 novel miRNAs in the plasma of…

A New Test for Mesothelioma?
| |

A New Test for Mesothelioma?

ByAlex Strauss

Malignant pleural mesothelioma, an aggressive cancer of the pleural membrane that encases the lungs, can be difficult to diagnose.  Early symptoms of the disease can be vague and mimic other lung conditions.  But the longer a patient goes without a firm diagnosis, the poorer the prognosis is likely to be since mesothelioma is resistant to many traditional therapies. In addition to considering the patient’s symptoms and history of asbestos exposure, doctors often rely on biomarkers – compounds found in the blood or lung fluid – to pinpoint mesothelioma. Now, a group of Danish scientists are investigating a new biomarker that may eventually allow for an earlier, more accurate, mesothelioma diagnosis. Methylthioadenosine phosphorylase (MTAP) is a key enzyme used to help cells…